Wyss Institute gets $16M to repurpose FDA-approved drugs for Covid-19
Excerpt from the article:
“As the scientific community races toward potential treatments for Covid-19, the respiratory illness caused by the novel coronavirus that has now killed at least 116,000 Americans, researchers at Harvard’s Wyss Institute are partnering with institutions across the U.S. on a new project using old materials.
The Wyss Institute has signed a one-year agreement worth up to $16 million with the U.S. Defense Advanced Research Projects Agency (DARPA) to identify and test FDA-approved drugs that could be repurposed to prevent or treat Covid-19. Scientists at Wyss are testing those drugs using Organ Chips, microfluidic devices lined with living human cells that were recently developed at the institute and are now produced by Wyss spinout Emulate.”
Click the button below to read the press release:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?